SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (468)12/20/2002 5:08:33 PM
From: Icebrg  Read Replies (1) | Respond to of 1022
 
Tumor penetration problems for mAbs.

There is a very good post over at Raging Bull summing up where ImmunoGen is (might be) standing in their efforts to develop their Tumor Activated Prodrugs. The problems discussed are however not restricted to ImmunoGen. They should apply to any company trying to develop mAb-based therapies to combat solid tumors.

I would welcome any comments to the discussion.

Erik

ragingbull.lycos.com